05:48 PM EDT, 04/17/2024 (MT Newswires) -- ImmunityBio ( IBRX ) filed an automatic shelf registration statement Wednesday for the potential sale of securities from time to time.

The filing covers its common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units.

ImmunityBio ( IBRX ) said it plans to use proceeds for advancing regulatory approvals, commercialization, clinical trials, research and development, capital expenditures and other general corporate purposes.